Details for Patent: 9,833,448
✉ Email this page to a colleague
Which drugs does patent 9,833,448 protect, and when does it expire?
Patent 9,833,448 protects UBRELVY and is included in one NDA.
This patent has sixty-four patent family members in forty-three countries.
Summary for Patent: 9,833,448
Title: | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Abstract: | The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved. |
Inventor(s): | Bell; Ian M. (Harleysville, PA), Fraley; Mark E. (North Wales, PA), Gallicchio; Steven N. (Horsham, PA), Ginnetti; Anthony (Perkasie, PA), Mitchell; Helen J. (Richboro, PA), Paone; Daniel V. (Lansdale, PA), Staas; Donnette D. (Harleysville, PA), Wang; Cheng (Fort Washington, PA), Zartman; C. Blair (Hatfield, PA) |
Assignee: | Merck Sharp & Dohme Corp. (Rahway, NJ) |
Application Number: | 15/293,569 |
Patent Claim Types: see list of patent claims | Use; Composition; | More… ↓ |
Drugs Protected by US Patent 9,833,448
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | UBRELVY | ubrogepant | TABLET;ORAL | 211765-001 | Dec 23, 2019 | RX | Yes | No | 9,833,448 | ⤷ Subscribe | ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS | ⤷ Subscribe | ||||
Abbvie | UBRELVY | ubrogepant | TABLET;ORAL | 211765-002 | Dec 23, 2019 | RX | Yes | Yes | 9,833,448 | ⤷ Subscribe | ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,833,448
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
European Patent Office | 2638042 | ⤷ Subscribe | 301248 | Netherlands | ⤷ Subscribe |
European Patent Office | 2638042 | ⤷ Subscribe | PA2023532 | Lithuania | ⤷ Subscribe |
European Patent Office | 2638042 | ⤷ Subscribe | CR 2023 00033 | Denmark | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |